Preferred Label : Anti-HER2/Anti-HER3 Bispecific Monoclonal Antibody MCLA-128;
Obsolete resource : true;
NCIt synonyms : Anti-HER2 x Anti-HER3 Bispecific Monoclonal Antibody MCLA-128;
NCIt definition : A full-length IgG1 bispecific antibody with enhanced antibody-dependent cellular cytotoxicity
(ADCC) directed against human epidermal growth factor receptor 2 (HER2; EGFR2, ERBB2)
and human epidermal growth factor receptor 3 (HER3; ErbB3), with potential antineoplastic
activity. Upon intravenous administration, the bispecific antibody docks on HER2,
and subsequently blocks heregulin-stimulated proliferation of tumor cells by binding
HER3. In addition to inhibiting HER3-dependent signaling, simultaneous targeting of
HER2 and HER3 by MCLA-128 may overcome a common resistance mechanism driven by heregulin-mediated
dimerization of HER2 and HER3. MCLA-128 is expected to eliminate tumor cells by recruiting
natural killer (NK) cells to tumor cells coated with the bispecific antibody.;
NCIt note : See 'Zenocutuzumab(C152948)';
Concept status : Retired_Concept;
Molecule name : MCLA 128; MCLA-128;
NCI Metathesaurus CUI : CL554335;
Origin ID : C153211;
UMLS CUI : C4549048;
See also inter- (CISMeF)
- Semantic type(s)
- UMLS correspondences (same concept)
